Bristol-Myers SquibbBMY
Market Cap: $98.7B
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Employees: 34,100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9% less call options, than puts
Call options by funds: $1.5B | Put options by funds: $1.65B
1.29% less ownership
Funds ownership: 76.88% [Q1] → 75.6% (-1.29%) [Q2]
5% less funds holding in top 10
Funds holding in top 10: 20 [Q1] → 19 (-1) [Q2]
9% less funds holding
Funds holding: 2,279 [Q1] → 2,083 (-196) [Q2]
24% less capital invested
Capital invested by funds: $84.3B [Q1] → $63.6B (-$20.6B) [Q2]
34% less repeat investments, than reductions
Existing positions increased: 669 | Existing positions reduced: 1,019
54% less first-time investments, than exits
New positions opened: 164 | Existing positions closed: 360
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Jefferies Akash Tewari 36% 1-year accuracy 5 / 14 met price target | 5%upside $51 | Hold Maintained | 28 Aug 2024 |
Barclays Carter Gould 64% 1-year accuracy 21 / 33 met price target | 14%downside $42 | Underweight Maintained | 22 Aug 2024 |
TD Cowen Steve Scala 50% 1-year accuracy 1 / 2 met price target | 9%upside $53 | Hold Maintained | 12 Aug 2024 |
Barclays Carter Gould 64% 1-year accuracy 21 / 33 met price target | 16%downside $41 | Underweight Downgraded | 29 Jul 2024 |
Deutsche Bank James Shin 100% 1-year accuracy 5 / 5 met price target | 8%downside $45 | Hold Maintained | 23 Jul 2024 |
Financial journalist opinion
Based on 39 articles about BMY published over the past 30 days